Chronic liver disease is a rapidly growing cause of morbidity and mortality worldwide, and this increase is largely driven by steatotic liver disease (SLD) comprising metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and MASLD and increased alcohol intake (MetALD). Hepatic steatosis and fibrosis are highly heritable and genetic variation has also been associated with the risk of hepatocellular carcinoma (HCC) and hepatic decompensation. This review summarizes the state of the art of genetics and genomics in SLD, with particular emphasis on potential clinical utility. Variants in/near genes including PNPLA3, TM6SF2, and HSD17B13 have been associated with cirrhosis and HCC in both MASLD and ALD, while others such as those in GCKR, TRIB1, and GPAM have been consistently associated with greater risk of hepatic steatosis in MASLD with much weaker effects if any on cirrhosis and HCC. While data on MetALD genetics are limited, we believe that the genetic risk factors for liver steatosis, cirrhosis, and HCC will be similar in MetALD compared to MASLD and ALD based on the largely shared genetic risk factors for MASLD and ALD. Finally, we discuss future directions in SLD genetics, notably genetically-defined disease subtypes, gene-environment interactions and their implications for therapy, and the utility of genetics in clinical risk stratification. Genetic studies have provided insight into important disease processes in SLD and may have an upcoming role in clinical care.
Citations
Citations to this article as recorded by
Hypothalamic Control of Liver Health and Disease: From Circuits to Pathophysiology and Therapies Qin Tang, Jiahui Li, Haiying Song, Ailin Zhang, Haifeng Zeng, Yining Xu, Li Mo, Jinhan He Advanced Science.2026;[Epub] CrossRef
PNPLA3 Is Associated With Hepatocellular Carcinoma, While a Five‐Variant Polygenic Risk Score Shows Limited Discrimination in Korean Patients With MASLD Jaejun Lee, Jung Hoon Cha, Hee Sun Cho, Hyun Yang, Mi Young Byun, Seok Keun Cho, Seong Wook Yang, Si Hyun Bae, Seung Up Kim, Su Jong Yu, Pil Soo Sung Journal of Gastroenterology and Hepatology.2026; 41(11): 3547. CrossRef
Alcohol-aware risk stratification and subtype-specific care pathways across metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease Hyo Young Lee, Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.0659. CrossRef
Steatotic liver disease spectrum: From MASLD to MetALD and beyond - Clinical outcomes and precision medicine frontiers Won Kim Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.1072. CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of hepatic decompensation and liver-related death, but most patients with MASLD do not develop these liver-related complications. Risk prediction and care pathways are crucial to identify which patients with MASLD are highest risk and link them to appropriate care. Risk prediction is usually done with blood-based algorithms such as Fibrosis-4, AST-platelet ratio index, and more recent scores such as steatosis-associated fibrosis estimator and LiverRisk Score. Second-line tests include enhanced liver fibrosis and imaging-based tests such as vibration-controlled transient elastography, shear wave elastography, or magnetic resonance elastography. We propose a consensus risk stratification care pathway that can be adapted for different clinical settings. We also discuss key needs to improve upon the state of the art: improving diagnosis/prognostic accuracy, especially of blood-based models, optimizing calibration, and ensuring interpretability of predictive models. Finally, we discuss recent advances in clinical decision support systems including best practice advisories, dashboards, and dynamic guidelines. We highlight factors critical to clinical decision support systems, including integration with existing systems and clinician workflows, minimizing additional burden to clinicians, provision of decision support and recommendations at the time/place of decision-making, and continuous evaluation and local user involvement.
Citations
Citations to this article as recorded by
Steatotic liver disease spectrum: From MASLD to MetALD and beyond - Clinical outcomes and precision medicine frontiers Won Kim Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.1072. CrossRef